Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Chiron Accepts Higher Bid from Novartis

by Michael McCoy
November 7, 2005 | A version of this story appeared in Volume 83, Issue 45

Vasella
[+]Enlarge
Credit: NOVARTIS PHOTO
Credit: NOVARTIS PHOTO

Vaccines

After eight weeks of resistance, the vaccine maker Chiron has accepted a sweetened offer by Novartis, the Swiss drug giant. Novartis will acquire the 58% of Chiron that it doesnt already own for $45.00 per share, or about $5.1 billion in cash.

Novartis, which has owned 42% of Chiron for some 10 years, first offered to acquire the rest of the company on Sept. 1 for $40.00 per share, or $4.5 billion. At the time, Chiron rejected the offer as inadequate (C&EN, Sept. 12, page 12).

With the deal, expected to be complete in first-half 2006, Novartis will get the worlds fifth largest vaccine maker, albeit one that has been beset by quality problems. Novartis CEO Daniel Vasella says his plan is to turn around the Chiron vaccine business, which will require investments in R&D and manufacturing to increase quality and capacity.

Big drugmakers are becoming interested in vaccines after years of indifference. Novartis, for example, cites forecasts that the global vaccine market is poised to double in size to more than $20 billion by 2009. Some of the growth is expected to come from pandemic preparedness. Late last month, the Department of Health & Human Services awarded Chiron a $62.5 million contract to manufacture a vaccine designed to protect against the H5N1 avian flu virus strain.

The agency earlier signed a $100 million bird flu vaccine contract with Sanofi-Aventis.

Chiron had overall sales last year of $1.7 billion, of which $510 million was in vaccines. The firm is also involved in blood testing and biopharmaceuticals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.